FREQUENTLYASKED QUESTIONS

About ERLEADA®

ERLEADA® is indicated for the treatment of patients with1:

  • Metastatic castration-sensitive prostate cancer (mCSPC)
  • Non-metastatic castration-resistant prostate cancer (nmCRPC)

Reference: 1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

ERLEADA® is an androgen-receptor (AR) inhibitor that inhibits AR signaling at multiple sites of action1:

  • Binds directly to the ligand-binding domain of the AR
  • Inhibits AR nuclear translocation
  • Inhibits DNA binding
  • Impedes AR-mediated transcription

Reference: 1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

  • The recommended dose of ERLEADA® is 240 mg (four 60 mg tablets) administered orally once daily1
  • Patients should also receive a GnRH analog concurrently or should have had a bilateral orchiectomy1
  • If a patient experiences a ≥Grade 3 toxicity or an intolerable side effect, hold dosing until symptoms improve to ≤Grade 1 or original grade, and then resume at the same dose or a reduced dose (180 mg or 120 mg), if warranted1

Find out more about dosing and administration

Reference: 1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

faq_icon